Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 20, 2025Cellular and Molecular Life SciencesOpen Access

IL-1 signaling and inflammasomes in acute myeloid leukemia: mechanisms and therapeutic opportunities

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAlessandra MortellaroSMSara MastaglioMMMarta Muzio

Discussion

Loading...

Member takes

Overview

Review highlights IL-1 signaling and inflammasomes in acute myeloid leukemia, suggesting new therapeutic targets and mechanisms of therapy resistance.

Key Points

  • The research reviews the role of IL-1 signaling and inflammasomes in acute myeloid leukemia (AML), focusing on therapeutic opportunities.
  • Review of preclinical and clinical studies targeting the IL-1 signaling pathway in AML.
  • Discussion of the role of inflammasomes, particularly NLRP3, in AML pathophysiology.
  • Examination of genetic mutations associated with AML and their implications in the microenvironment.
  • IL-1 is identified as a potential tumor driver in AML, influencing therapy resistance.
  • NLRP3 inflammasome plays a significant role in regulating IL-1β release and cellular stress responses.
  • Identifying targeting strategies for IL-1 signaling may provide new therapeutic opportunities in treating AML.

Cite This Study

Mortellaro et al. (2025) studied this question.

synapsesocial.com/papers/6945ea41742299010fff02e7https://doi.org/10.1007/s00018-025-05966-5
View Full Paper
Ask AI
Bookmark
Share